XML 49 R37.htm IDEA: XBRL DOCUMENT
v3.25.3

Segment Information (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2025
Segment Reporting [Abstract] |
Schedule of Segment Reporting Information, by Segment |
| Three Months Ended September 30, |  | Nine Months Ended September 30, |  |
| 2025 |  | 2024 |  | 2025 |  | 2024 |  |
Revenue | $ | — |  |  | $ | — |  |  | $ | 70 |  |  | $ | — |  |  |
Operating Expenses: |  |  |  |  |  |  |  |  |
Research and development by significant expense: |  |  |  |  |  |  |  |  |
BOLSTER trial | 829 |  |  | 475 |  |  | 2,222 |  |  | 2,820 |  |  |
ASCEND trial | 8 |  |  | 133 |  |  | 61 |  |  | 271 |  |  |
Chemistry, manufacturing and controls | 157 |  |  | 764 |  |  | 543 |  |  | 1,703 |  |  |
Clinical department | 654 |  |  | 1,001 |  |  | 2,802 |  |  | 3,191 |  |  |
Other (1) | 311 |  |  | 169 |  |  | 1,187 |  |  | 399 |  |  |
Research and development | 1,959 |  |  | 2,542 |  |  | 6,815 |  |  | 8,384 |  |  |
General and administrative by significant expense: |  |  |  |  |  |  |  |  |
Corporate | 1,068 |  |  | 1,183 |  |  | 3,370 |  |  | 3,587 |  |  |
Investor relations/public relations/communications | 306 |  |  | 338 |  |  | 946 |  |  | 969 |  |  |
Finance | 539 |  |  | 562 |  |  | 1,706 |  |  | 1,727 |  |  |
Legal | 183 |  |  | 174 |  |  | 734 |  |  | 1,084 |  |  |
Business development | 134 |  |  | 120 |  |  | 401 |  |  | 437 |  |  |
Share based compensation expense | 195 |  |  | 292 |  |  | 811 |  |  | 860 |  |  |
Other (2) | 30 |  |  | 125 |  |  | 417 |  |  | 412 |  |  |
General and administrative | 2,455 |  |  | 2,794 |  |  | 8,385 |  |  | 9,076 |  |  |
Operating loss | (4,414) |  |  | (5,336) |  |  | (15,130) |  |  | (17,460) |  |  |
Other income, net | 165 |  |  | 406 |  |  | 536 |  |  | 1,287 |  |  |
Benefit from income taxes | — |  |  | — |  |  | (962) |  |  | (798) |  |  |
Net loss | $ | (4,249) |  |  | $ | (4,930) |  |  | $ | (13,632) |  |  | $ | (15,375) |  |  |
Cash, cash equivalents, and marketable securities |  |  |  | $ | 18,998 |  |  | $ | 35,856 |  |  |
(1) Included in Other are the GBM study, FORTIFIDE study and research oncology expenses |  |  |  |  |  |  |  |  |
(2) Included in Other are facilities expense, human resource and information technology expenses |  |  |  |  |  |  |  |  |

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration